Application of beta-glucan combined with anti-tumor drug in anti-tumor treatment

An anti-tumor drug, glucan technology, used in anti-tumor drugs, drug combinations, antibody medical ingredients, etc.

Inactive Publication Date: 2021-02-09
CHANGZHOU NO 2 PEOPLES HOSPITAL
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Although existing studies have shown that polysaccharides, especially β-glucan, a yeast-derived β-glucan polysaccharide (β-(1,3)(1,6)-glucan) , it acts as an immunomodulator, but there are no relevant reports and studies on the application of being developed for the combined administration of anti-tumor drugs in anti-tumor therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of beta-glucan combined with anti-tumor drug in anti-tumor treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Effect of β-glucan in combination with anti-angiogenic drugs on tumor growth:

[0042] Tumor angiogenesis alters immune function in the tumor immune microenvironment, resulting in an immunosuppressive microenvironment. Anti-angiogenic drugs, such as anti-VEGFR2 antibody anti-V, have been proven to be effective in tumor treatment. Since β-glucan can transform the immunosuppressive environment into a favorable anti-tumor environment, it was co-administered with anti-V in the treatment of LLC non-small cell lung cancer (NSCLC) mouse subcutaneous xenograft tumor model to enhance anti-V antibody Efficacy.

[0043] 0.1 mL (2×10 6 ) LLC tumor cells. When the mouse tumor volume is 150mm 3 At the same time, treat according to the following regimen twice a week: 0.1mL / solvent; 1mg / β-glucan; 10mg / kg or 20mg / kg anti-V. Blood samples were collected on day 10 and 2 hours after the last treatment. Treatment groups included vehicle group (PBS control), β-glucan alone group, anti-...

Embodiment 2

[0045] Coadministration of β-glucan with anti-PD-1 antibody improves tumor-free survival:

[0046] In another animal study, mice were injected with tumor cells EO771 and then randomized. 8-10 week female mice were subcutaneously injected with 3×10 6 Cells (resuspended in 0.1 ml). EO771 is a breast cancer cell with low expression of PD-1. From the third day, start treatment twice a week: 0.1ml / solvent; 1mg / β-glucan; 100μg / anti-PD-1 monoclonal antibody.

[0047] Treatment groups included vehicle group (PBS control), β-glucan alone group, anti-PD-1 antibody alone group, anti-PD-1 antibody+β-glucan group. When the mouse tumor volume reaches 150mm 3 , randomly grouped. The results are shown in Table 1.

[0048] Treatment Groups Tumor-free Survivors (Day 30) PBS 1 / 16 Glucan 3 / 15 Anti-PD-1 4 / 15 Anti-PD-1+Glucan 14 / 16

[0049] Similarly, anti-PD-1 antibody combined with β-glucan can produce a synergistic effect and effectively prolong dis...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of anti-tumor treatment drugs, in particular to application of beta-glucan combined with an anti-tumor drug in anti-tumor treatment. Beta-glucan is beta-glucan polysaccharide derived from yeast and comprises beta-1,3 / 1,6 glucan, and structurally, a yeast beta-glucan main chain is formed by connecting glucose monomers through beta-(1, 3) bonds, and a side chain is connected to the main chain by glucose through a beta-(1, 6) glycosidic bond; and beta-glucan and an antibody or a small molecule drug are applied in a combined mode, the anti-tumor effectis achieved by improving the tumor immune microenvironment, beta-glucan can promote natural immune effector cells to kill complement-conditioned tumor cells through a complement CR3 dependence mechanism, and multiple animal tumor models show that compared with any monotherapy, the situation that the beta-glucan and a complement activator or an anti-tumor antibody are combined for treatment can remarkably delay the tumor growth, and the total lifetime can be prolonged.

Description

technical field [0001] The invention relates to the technical field of anti-tumor drugs, in particular to the application of β-glucan combined with anti-tumor drugs in anti-tumor therapy. Background technique [0002] For the treatment of cancer (malignant tumor), traditional radiotherapy and chemotherapy often have common blood system toxicity such as myelosuppression, immunosuppression, and leukopenia. In recent years, immunotherapy (Immunotherapy), including cell therapy, vaccine therapy, antibody drug therapy, etc., as the fourth cancer treatment method after surgery, chemotherapy and radiotherapy, will gradually become the main means of cancer treatment. Among them, polysaccharides (especially β-glucan) extracted from fungi are used as typical biological response modifiers (Biological Response Modifiers, BRMs) or immunomodulators (Immunomodulators) to indirectly achieve anti-tumor effects by mobilizing the body's immune system. The more attention it receives, the more ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/716A61K45/06A61K39/395A61P35/00
CPCA61K31/716A61K39/39558A61K45/06A61P35/00A61K2300/00
Inventor 戚春建宁永玲丁骏
Owner CHANGZHOU NO 2 PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap